ArticleBiomaterials2026
Identification and characterization of a Fibrillin-1 derived matrikine for cardiac regeneration and repair.
Article in Biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
9 authors.
Funding
Abstract
The development of regenerative strategies to repair the heart is of high importance. Our lab has shown that extracellular matrix derived from decellularized fetal myocardium promotes neonatal cardiomyocyte proliferation in vitro. The goal of this study was to identify specific peptide(s)/protein(s) in solubilized cardiac ECM responsible for this proliferative effect. We hypothesized that isolation and then treatment with one or more small synthetic peptide derived from this source could replicate the cellular response to whole solubilized ECM. Decellularized fetal and adult rat hearts were fractionated by molecular weight using SDS-PAGE and transferred to PVDF membranes. Analysis of cardiomyocytes cultured on the membranes revealed regions of enhanced cardiomyocyte proliferation. Subsequent isolation and proteomic analysis of the protein bands that that correlated with proliferative regions identified fibrillin-1 as the predominant ECM protein associated with these regions of cardiomyocyte proliferation. One region (residues 55-86) of fibrillin-1 was synthesized as a peptide and tested for a direct effect on cardiomyocyte proliferation. Compared to positive and negative controls, as well as scrambled and alkylated versions, this peptide led to 3-4-fold increase in cardiomyocyte proliferation. Analysis of the amino acid sequence demonstrated high homology with latent-TGF-β binding proteins and subsequent experiments showed that the matrikine could also reduce TGF-β induced activation of cardiac fibroblasts. These data suggest that individual peptides derived from soluble ECM could have utility as a novel therapeutic for cardiac tissue engineering and regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.